Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234283 | 0.88 | CHRM1 (0.65) | CHRM1MAPTTP53FABP4LMNA | |
| SCHEMBL3234254 | 0.88 | CHRM1 (0.59) | CHRM1MAPTADRA1DALDH1A1KDM4E | |
| SCHEMBL2877658 | 0.87 | CHRM1 (0.62) | CHRM1LMNA | |
| SCHEMBL16341817 | 0.86 | CHRM1 (1.00) | CHRM1LMNAALDH1A1KDM4EHPGD | |
| SCHEMBL3234654 | 0.86 | CHRM1 (0.57) | CHRM1MAPTADRA1DTP53KMT2A | |
| SCHEMBL2877481 | 0.85 | CHRM1 (0.86) | CHRM1MAPTLMNA | |
| SCHEMBL2880256 | 0.85 | CHRM1 (0.76) | CHRM1LMNARAB9AP2RX7 | |
| SCHEMBL2485404 | 0.83 | CHRM1 (0.93) | CHRM1LMNA | |
| SCHEMBL2877807 | 0.83 | CHRM1 (0.74) | CHRM1LMNAALDH1A1 | |
| SCHEMBL2877150 | 0.83 | CHRM1 (0.64) | CHRM1MAPTTP53FABP4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | claimed |
| US-20100317692-A1 | Quinolone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2010-12-16 | — | — | US | claimed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | claimed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389545-B2 | Quinolone M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1963271-B1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1963271-A1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck & Co., Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007100366-A2 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100366-A2 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007067489-A1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067489-A1 | QUINOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK & CO., INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317692-A1 | Quinolone M1 Receptor Positive Allosteric Modulators | CHRM1, CHRM2, MTNR1A | CHRM1 1/4885MAPT 293/4885ADRA1D 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.